Cyclo-Oxygenase-2 Inhibitors and the Kidney
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 25 (3) , 165-172
- https://doi.org/10.2165/00002018-200225030-00003
Abstract
Cyclo-oxygenase (COX) is one of the key enzymes in the biosynthesis of prostaglandins. Two isoforms of this enzyme COX-1 and COX-2 are known to exist. Among other functions, prostaglandins play an important role in the protection of the gastric mucosa and maintenance of renal function in pathophysiological conditions which would otherwise threaten it. Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin synthesis, resulting in gastric mucosal injury and renal dysfunction in susceptible individuals. The recent introduction of selective COX-2 inhibitors, celecoxib and rofecoxib, appear to induce less gastrointestinal morbidity. Although conclusive data are still lacking, there is evidence to suggest that COX-2 antagonists may be capable of causing some of the same renal syndromes seen in association with the older, less selective NSAIDs.Keywords
This publication has 40 references indexed in Scilit:
- Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharideCell and tissue research, 2001
- Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null miceKidney International, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamicsJournal Of Hypertension, 2000
- Are selective COX-2 inhibitors nephrotoxic?American Journal of Kidney Diseases, 2000
- Natriuretic Response to Increased Pressure Is Preserved With COX-2 InhibitorsHypertension, 1999
- Cyclooxygenase-2 Mediates Increased Renal Renin Content Induced by Low-Sodium DietHypertension, 1997
- An Open Study to Assess the Safety and Tolerability of Meloxicam 15 mg in Subjects with Rheumatic Disease and Mild Renal ImpairmentRheumatology, 1996
- Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs on the KidneyMedical Clinics of North America, 1984
- Nonsteroidal Antiinflammatory Drugs and Renal FunctionAnnual Review of Medicine, 1984